Clinical Trial Update: Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy [Phase 2]

View source ↗

Summary

This Phase II trial of lurbinectedin plus avelumab as switch-maintenance first-line therapy for metastatic urothelial carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• BAVENCIO (AVELUMAB)
• Zepzelca (lurbinectedin)

Snippet

Sponsor: AdventHealth | Conditions: Metastatic Cancer, Urothelial Carcinoma | Phase 2 | Status: WITHDRAWN